Chugai Pharmaceutical Co.

The Chugai Pharmaceutical Co., Ltd. (中外製薬株式会社, Chūgai Seiyaku kabushiki gaisha) is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014.[1] The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO.

Chugai Pharmaceutical
Native name
中外製薬株式会社
Chūgai Seiyaku kabushiki gaisha
Public KK
Traded as
ISINJP3519400000 
IndustryPharmaceutical Industry, Business import, production and development of drugs for medical sales
FoundedMarch 8, 1943
HeadquartersNihonbashi Mitsui Tower, Nihonbashi Muromachi 2-1-1, Chūō, Tokyo
On the registration Headquarter: Tokyo Kita (Tokyo)
Key people
Osamu Nagayama - Chairman and Tatsuro Kosaka - CEO
Revenue72.9 billion capital of 47 million yen. Standalone sales of 329.2 billion yen and 344.8 billion yen consolidated
(December 2007)
ParentHoffmann-La Roche (61.62%)
Websitewww.chugai-pharm.co.jp (in Japanese)

History
  • 1961 developed patents for synthesis of vitamin A
  • 1995 acute promyelocytic sphere of drug treatment leukemia Vesanoid was released.
  • 1996 anti-viral chemotherapeutic agent Hivid released (HIV reverse transcriptase inhibitor)
  • 1997 – HIV protease inhibitor Invirase released
  • 1999 – immunosuppressive agent Cellcept released
  • 2000 – Release of an antiemetic drug Kytril, developed to combat the side effects of chemotherapy
  • 2001 – Produced an anti-influenza virus Tamiflu (Roche)
  • 2011 - Produced Actemra, a human IL-6 receptor monoclonal antibody for rheumatoid arthritis
  • 2015 – In March the company announced it would co-commercialise Athersys's stem cell therapy for ischemic strokes in Japan. The deal could yield upwards of US$205 million.[2]

See also
  • Biotech and pharmaceutical companies in the New York metropolitan area

References
  1. Cortez, Michelle Fay; Matsuyama, Kanoko (25 August 2014). "Roche Said to Have Decided Against Bid for Rest of Chugai". Bloomberg.
  2. Staff (2 March 2015). "Chugai to Co-Develop Athersys' Cell Therapy in Japan in Up-to-$205M Partnership". Genetic Engineering & Biotechnology News (Paper, Vol 35, i 7, p. 12). Retrieved 11 June 2016.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.